Growtropin Worth 1 Billion Won Provided to 157 Children with Growth Disorders

On March 27, Dong-A ST announced that it held the '2026 Growth Hormone Donation Ceremony' at its headquarters in Dongdaemun-gu, Seoul, and will provide the growth hormone drug 'Growtropin' worth 1 billion won to 157 children with growth disorders.

On the 27th, at Dong-A ST headquarters in Dongdaemun-gu, Seoul, Jeong Jaehoon, CEO of Dong-A ST (left), and Roh Huisik, founder of Hanmaeum Social Welfare Foundation, are taking a commemorative photo at the "2026 Growth Hormone Donation Ceremony." Dong-A ST

On the 27th, at Dong-A ST headquarters in Dongdaemun-gu, Seoul, Jeong Jaehoon, CEO of Dong-A ST (left), and Roh Huisik, founder of Hanmaeum Social Welfare Foundation, are taking a commemorative photo at the "2026 Growth Hormone Donation Ceremony." Dong-A ST

View original image

Dong-A ST will deliver the growth hormone medication 'Growtropin-II Injection Solution iPen 30IU' to the Hanmaeum Social Welfare Foundation. The foundation will select recipients through recommendations from pediatric endocrinology specialists and a document review process. Children from low-income families diagnosed with growth disorders who are selected as recipients will receive the necessary growth hormone medication for one year of treatment.


Growth disorders occur in about 3% of all children, and among them, approximately 20% have pathological growth disorders such as growth hormone deficiency, idiopathic short stature, or chromosomal abnormalities. Dong-A ST has been running a support program for children with growth disorders since 2013. Up until last year, the company provided growth hormone medication worth about 8 billion won to more than 1,300 children.



A Dong-A ST representative stated, "We will continue to support more children so they can grow up healthy by providing growth hormone medication."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing